3 Healthcare Pathbreakers With Long-Term Tailwinds These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.
Argenx Tops Buy Point On Bullish Study, 850 Price Target Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage.
Argenx Targets FDA Label Expansion After Vyvgart Trial Success Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025
ARGENX SE - ADR (NASDAQ:ARGX) Ticks Key Boxes for Growth Investors Using Navellier's 'Little Book' Strategy Discover ARGX, a top growth stock matching Navellier's criteria with explosive earnings growth, soaring sales, and a high 21% ROE.
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
